Changes in Hong Kong stocks | Changfeng Pharmaceutical (02652) rose more than 5% to complete the placement of 21.747,700 new H shares ICF001, which is expected to fill the clinical gap in the treatment of PH-ILD

The Zhitong Finance App learned that Changfeng Pharmaceutical (02652) rose by more than 5%. As of press release, it had risen 4.84% to HK$16.89, with a turnover of HK$65,397,700.

According to the news, Changfeng Pharmaceutical announced that it has completed the placement of 21.7477 million new H shares on August 6, 2026. The placement price is HK$1,382 per H share, with a net raise of approximately HK$295 million. According to previous company announcements, about 70% of the net fundraising was used for the clinical and pre-clinical development of the Group's innovative drug candidates; about 15% was used to develop CMC research, clinical research, drug delivery device development, and registration and regulatory reporting expenses for the Group's complex inhalation products (including CF048, CF059/CF060, CF066 EDS, CF067, CF068 and CF011/CF088) on a global scale.

According to reports, Changfeng Pharmaceutical has established a complete inhalation formulation platform covering R&D, production and global registration. It also has R&D and production capabilities for various technical paths such as nebulizers, aerosols, powders, nasal sprays, inhalation sprays, micronucleic acids, and liposome inhalation delivery, forming a complete advanced path from multi-dosage platform construction to original research and innovation. The company's self-developed ICF001 new drug clinical trial application has been officially accepted by the State Drug Administration. At present, no specific drug has been approved in the domestic PH-ILD field. ICF001 is expected to become the first inhaled drug approved for the treatment of PH-ILD in China, filling this clinical gap.